- Open Access
Transgenically mediated shRNAs targeting conserved regions of foot-and-mouth disease virus provide heritable resistance in porcine cell lines and suckling mice
© Jiao et al.; licensee BioMed Central Ltd. 2013
- Received: 16 January 2013
- Accepted: 7 June 2013
- Published: 3 July 2013
Foot-and-mouth disease virus (FMDV) is responsible for substantial economic losses in livestock breeding each year, and the development of new strategies is needed to overcome the limitations of existing vaccines and antiviral drugs. In this study, we evaluated the antiviral potential of transgenic porcine cells and suckling mice that simultaneously expressed two short-hairpin RNAs (shRNAs) targeting the conserved regions of the viral polymerase protein 3D and the non-structural protein 2B. First, two recombinant shRNA-expressing plasmids, PB-EN3D2B and PB-N3D2B, were constructed and the efficiency of the constructs for suppressing an artificial target was demonstrated in BHK-21 cells. We then integrated PB-EN3D2B into the genome of the porcine cell line IBRS-2 using the piggyBac transposon system, and stable monoclonal transgenic cell lines (MTCL) were selected. Of the 6 MTCL that were used in the antiviral assay, 3 exhibited significant resistance with suppressing ratios of more than 94% at 48 hours post-challenge (hpc) to both serotype O and serotype Asia 1 FMDV. MTCL IB-3D2B-6 displayed the strongest antiviral activity, which resulted in 100% inhibition of FMDV replication until 72 hpc. Moreover, the shRNA-expressing fragment of PB-N3D2B was integrated into the mouse genome by DNA microinjection to produce transgenic mice. When challenged with serotype O FMDV, the offspring of the transgenic mouse lines N3D2B-18 and N3D2B-81 exhibited higher survival rates of 19% to 27% relative to their non-transgenic littermates. The results suggest that these heritable shRNAs were able to suppress FMDV replication in the transgenic cell lines and suckling mice.
- Virus Challenge
- Transgenic Cell Line
- Suckling Mouse
- FMDV Infection
- Strong Antiviral Activity
Foot-and-mouth disease (FMD) is a highly contagious disease that affects more than 33 species of cloven-hoofed animals, such as swine, cattle and other livestock. FMD outbreaks often cause severe economic losses due to reduced productivity and the required slaughter of millions of infected or susceptible animals, and these outbreaks have even raised political disputes concerning trade embargos on animal products. Therefore, this disease is designated by the International Office of Epizootics (OIE) as a serious disease that spreads rapidly and requires socioeconomic considerations. The FMD virus (FMDV) belongs to the genus Aphthovirus within the family Picornaviridae. The FMDV genome is composed of a positive-sense, single-stranded RNA molecule of approximately 8500 nucleotides and contains a unique large open reading frame.
The most commonly used strategies for controlling FMD outbreaks are routine vaccination and slaughtering of infected animals. However, livestock slaughter results in substantial economic losses. The application of inactivated and attenuated vaccines causes a risk for live or revertant viruses to escape[3, 4]. RNAi is a gene silencing mechanism that has been found in all eukaryotes. Double-stranded small interfering RNA (siRNA) molecules or folded short-hairpin RNA (shRNA) can induce the specific degradation of complementary messenger RNA. Because of the rapidity and specificity of its effects, RNAi has been exploited as a promising technology for the control of important pathogens, including human immunodeficiency virus (HIV), herpes simplex virus (HSV) and hepatitis B virus (HBV)[7–9].
Previous studies conducted in our lab and by other groups have investigated the inhibitory effect of siRNA on FMDV replication both in vitro and in vivo[10–12]. However, like other RNA viruses, FMDV undergoes rapid mutation and is antigenically variable. Furthermore, there are seven distinguishable serological types (A, O, C, Asia 1, SAT 1, SAT 2, and SAT 3) and more than 65 subtypes. Thus, one major issue in establishing RNAi as a viable approach to combat FMDV is the high genetic polymorphism exhibited by this virus. Therefore, the strategy of combining multiple siRNA/shRNA and designing shRNA that target the conserved regions of the viral genome has been suggested[14–17]. The non-structural protein genes of FMDV, such as 3D, 2B and 3C, may serve as potential targets of these shRNAs.
Another crucial issue is the designing of an optimal transfer vector for the delivery of shRNA-expressing cassettes. Chen et al. demonstrated that the replication-defective human adenovirus type 5 (rAd5), which expresses antiviral shRNA, significantly reduced the susceptibility of guinea pigs and swine to FMDV infection. Cong et al. showed that an attenuated Salmonella choleraesuis (C500) vaccine strain carrying an shRNA-expressing plasmid was capable of inhibiting FMDV replication in vivo. Nevertheless, these methods are still limited because the vectors only work for a short period of time in animals. An alternative strategy is to establish a transgenic RNAi system by breeding genetically modified species. Recent developments in plants and insects have demonstrated that heritable RNAi can induce the resistance to some infectious diseases. In animals, Golding et al. attempted to produce transgenic cattle that expressed an shRNA that targeted the prion protein. Wang et al. also reported some reduction of infectious symptoms in transgenic mice that expressed a single shRNA against FMDV, indicating the feasibility of this transgenic system.
In this study, we constructed recombinant plasmids that could simultaneously express two shRNAs that targeted the conserved regions of the viral polymerase protein 3D and the non-structural protein 2B. The piggyBac transposon system was used as the transgenic vector in the porcine cell line IBRS-2, and up to 100% inhibition of the FMDV replication was observed in the resulting transgenic cell lines. This antiviral capacity was effective against both serotype O and serotype Asia 1 FMDV, and it was not directly affected by the transgene copy number. In addition, after the germ-line microinjection of the linearized plasmids, the offspring of two transgenic mouse lines exhibited enhanced resistance against serotype O FMDV infection.
Plasmids, cells, and viruses
All the experiments involving virus challenge in mice were approved by the animal ethics committee of Lanzhou Veterinary Research Institute and followed both the national guidelines for the use of animals in scientific research and the standard protocol described by the OIE.
The piggyBac transposon plasmid PB[Act-RFP]DS, PB[PGK-Neo] and the helper plasmid CMV-PBase were kindly provided by Prof. Xiaohui Wu. IBRS-2 cells (swine kidney cells) and all of the IBRS-2-derived transgenic cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Carlsbad, USA) supplemented with 5% heat-inactivated fetal bovine serum (FBS) and adjusted to pH 7.4. BHK-21 cells (hamster kidney cells) were also cultured in DMEM but with 10% FBS. The cultures were incubated at 37°C with 5% CO2. FMDV isolates of serotype O/HKN/2002 [GenBank: AY317098] and serotype Asia 1/Jiangsu/2005 [GenBank: EF149009] were used for the viral challenge experiments.
Construction of shRNA-coding vectors
The 3D-shRNA-expressing cassette was modified from the pPOL plasmid, a construct previously generated by our lab. A revised mouse U6 promoter (mU6) was PCR-amplified and cloned into pPOL, replacing the original U6 promoter. The 56-bp 3D-specific shRNA-coding region inserted after the mU6 promoter was also modified to 5’-GAGGCCATCCTCTCCTTTGCACGCCGTGGGACCATACAGGAGAAGTTGATCTCCGT-3’ (sense, corresponding to nt 1225 to 1280 of O/HKN/2002 3D). Finally, the Hind III site after the transcriptional terminal signal of five T residues was excised by Klenow (large fragment) treatment and blunt end ligation. A lacZ-shRNA-expressing cassette was constructed in the same manner using pLacZ as a control for non-specific RNAi.
The 2B-shRNA-expressing cassette was driven by a human H1 promoter (hH1), which was cloned by PCR amplification from human genomic DNA extracted from 293 T cells with the Axygen Genomic DNA Kit (Corning, Tewksbury, USA). Inverted repeats representing the 2B-shRNA or the heterologous NTH21-shRNA were inserted after the H1 promoter along with the type III RNA polymerase terminal signal of the five T residues. The 25-bp 2B-specific shRNA was 5’-CCAGATGCAGGAGGATATGTCAACA-3’ (sense, corresponding to nt 57 to 81 of O/HKN/2002 2AB), which was also rearranged based on previous work performed by our lab. The 21-bp sequence of the heterologous NTH21-shRNA has been described previously.
The reporter gene cassette of EGFP was obtained by cloning the mouse phosphoglycerate kinase (PGK) promoter into pEGFP-N1, replacing the CMV promoter. The resulting pPGK-EGFP-N1 plasmid was digested with Apa I and Afl II. The neo-resistance (Neo-R) cassette was PCR amplified from pEGFP-N1 along with the designated terminal restriction enzyme sites.
Analysis of the repression effects induced by shRNA-coding vectors against target EGFP expression in BHK-21 cells
The PCR primers used for detection and qPCR of transgenic cells and mice
Quantitate GFP in BHK-21 cells
Quantitate β-actin in BHK-21 cells
Detect PBL in cell lines
Detect PBR in cell lines
Detect transposase in cell lines
Quantitate copy number in cell lines
Detect transgenic mice
Detect transgenic mice
Quantitate copy number in mice
Quantitate GAPDH as reference in mice
Preparation and identification of monoclonal transgenic cell lines
IBRS-2 cells were seeded in 24-well plates, and 0.2 μg of plasmid PB-EN3D2B (or PB-ENlacZNH21) together with 0.2 μg of the transposase-expressing helper plasmid CMV-PBase were co-transfected into each well using Lipofectamine 2000. After 24 h of incubation, the cells were digested and approximately 1/20 to 1/40 of the cells in a single well were added to a 10-cm plate containing DMEM and 5% FBS. On the following day, the medium was replaced with DMEM containing 5% FBS and 300 μg/mL G418 (Sigma-Aldrich, St.Louis, USA). After 12–14 days of incubation, monoclonal colonies were individually collected with clone cylinders and transferred to 48-well plates. The genomic DNA of each monoclonal cell line was extracted using an Axygen Genomic DNA Kit. The primer pairs PBL1F/PBL1R and PBR1F/PBR1R, which amplify specific fragments in the left and right transposon arms, respectively, were used to identify the transgenic cell lines (Table 1 and Figure 1A). PCR tests using the primers PBase-F and PBase-R were performed at the same time to ensure that the gene encoding transposase had not been inserted. The resulting MTCL generated from the plasmids PB-EN3D2B and PB-ENlacZNH21 were named IB-3D2B and IB-lacZNH, respectively.
To detect the transgene copy numbers in the MTCL, genomic DNA samples were used as templates for qPCR with the primers Q-PBR1-F and Q-PBR1-R to amplify a 229-bp fragment of the right transposon arm (PBR). The results were normalized to the absolute amount of DNA in each sample.
Production and selection of transgenic mice
For germ-line transgenesis, female Kunming White (KM) mice that had been pretreated with PMSG (pregnant mare serum gonadotropin) and HCG (human chorionic gonadotropin, Sigma-Aldrich) were mated with male KM mice as fertilized egg donors. The 2.5-kb Asc I-Hind III fragment of the plasmid PB-N3D2B (Figure 1C) was purified and diluted to a concentration of 2 ng/μL. After the male pronucleus was microinjected with the DNA solution, the eggs were transferred into the oviducts of pseudopregnant KM females to generate transgenic mice.
Tail tips (approximately 1-cm long) were collected from all of the mice offspring at 3 weeks of age and incubated at 56°C in a buffer of 50 mM Tris (pH 8.0), 100 mM EDTA, 100 mM NaCl, 1% SDS and 0.5 mg/mL protease K. After 3 h, the mouse genomic DNA was isolated by phenol-chloroform extraction and ethanol precipitation. The DNA samples were then dissolved in TE (pH 8.0), and the transgenic status of the mice was examined using PCR amplification with the primer pairs 3D-Neo-F/3D-Neo-R and Neo-2B-F/Neo-2B-R (Table 1 and Figure 1C), which could detect the presence of the 3D and 2B-shRNA cassettes. The transgene copy numbers in transgenic mice were examined by qPCR using the corresponding primers and with GAPDH as the reference gene. All transgenic founder mice were crossed with wild-type (WT) KM mice to maintain the descendants as hemizygotes.
Virus challenge in transgenic cell lines
The 50% tissue culture infective doses (TCID50) of FMDV were calculated using the Reed-Muench formula. Viral suspensions of 106 to 107 TCID50/mL were used for the experiments. To assess the antiviral capacity of the MTCL, each of the cell lines was seeded in 96-well plates. On the following day, 20 or 50 TCID50 of FMDV diluted in 0.1 mL DMEM without FBS were added to the monolayers. After one hour of absorption, the virus dilutions were removed, and the cells were washed with DMEM and then incubated at 37°C with 5% CO2. The cytopathic effects (CPE) were examined microscopically over 3 days. Supernatant fluids were harvested at various times after infection, and viral titers (i.e., TCID50) at 24-h intervals were determined three times in BHK-21 cells.
Virus challenge in transgenic suckling mice
Suckling mice (2 to 3 days old) were inoculated with four 10-fold serially diluted virus solutions (i.e., 10-6, 10-7, 10-8, and 10-9) in phosphate-buffered saline (PBS) by subcutaneous injection in the neck area. The 50% lethal dose (LD50) was estimated using the Reed-Muench method. To investigate the antiviral capacities of the transgenic mice, hemizygous male mice from transgenic mouse lines were crossed with WT female KM mice, and the newborn offspring (with a transgenic ratio of approximately 50%) were challenged with different doses of FMDV in 0.2 mL of PBS by subcutaneous injection. Tail samples were collected from every suckling mouse one day before the virus challenge. After the 5 days of observation, the genomic DNA extraction and transgenic-status differentiation were performed as described above. The survival rate of the transgenic mice was recorded, and their non-transgenic littermates were used as controls.
GraphPad Prism 5.0 software was used for all the statistical analyses.
The shRNA-coding vectors effectively suppressed target fusion GFP protein expression in BHK-21 cells
Establishment of shRNA-expressing monoclonal transgenic cell lines
The shRNA genes conferred resistance against serotype O FMDV infection in transgenic cell lines
To further study the antiviral potential of the MTCL, the three transgenic cell lines IB-3D2B-2, IB-3D2B-3, and IB-3D2B-6 were challenged with 50 TCID50 of FMDV O/HKN/2002, and normal IBRS-2 cells were used as controls. Microscopic examination revealed that there was an obvious delay in the CPE development in IB-3D2B-2 and IB-3D2B-3 cells challenged with 50 TCID50 of virus, whereas the IB-3D2B-6 cells, which had stronger antiviral activity, failed to develop any CPE after 3 days of observation (Figure 4B). The virus was not detectable in the supernatant fluid of IB-3D2B-6 cells. IB-3D2B-2 and IB-3D2B-3 also showed significantly reduced titers within 48 hpc (at least 95% of reduction, Figure 5B and C).
The shRNA genes provided inhibitory effects against serotype Asia 1 FMDV in the transgenic cell lines
The shRNA gene copy number does not directly affect the degree of resistance in the transgenic cell lines
Correlation between transgene copy numbers and antiviral capacities of the MTCL.
Anti-FMDV shRNA enhanced the survival rates of transgenic suckling mice after virus challenge
Survival rates of suckling mice from different transgenic mouse lines challenged with serotype O FMDV
Transgenic suckling mice
Although the technique for producing transgenic animals that express shRNA was first reported in 2002[26–28], few studies have explored the prevention of virus replication in mammals using this strategy. Wang et al. attempted to generate a transgenic mouse model containing a single anti-FMDV shRNA gene. Immunohistochemical assays demonstrated a reduction of the virus in the tissues of infected adult primary transgenic mice. Another report by Wang and Wu discussed the antiviral potential of shRNA-expressing cells and primary cells from transgenic bovine fetuses made by lenti-virus insertion. However, no reports have evaluated whether the transgenic FMDV-susceptible animals and their transgenic offspring were capable of resisting to viral infection. In this study, we constructed plasmids that simultaneously encoded two shRNAs that targeted conserved regions of the FMDV genome. The results demonstrated that the plasmid PB-N3D2B was able to effectively suppress an artificial target in vitro, and transgenic modification with these plasmids provided strong antiviral capacity in repeatedly passaged cell lines and enhanced resistance against FMDV infection in offspring suckling mice. Our present experimental data suggest that transgenic RNAi is worthy of pursuit as a strategy for producing animals resistant to FMDV.
The method of combining multiple conserved region-targeting siRNA/shRNA has been the preferred antiviral strategy because one shRNA can complement the other, with the added benefit of potentially suppressing mutated or heterologous viruses[16, 30]. Notably, there is evidence that the co-expression of multiple shRNAs from a single construct appears to be more effective than simply mixing single shRNAs. In this investigation, we simultaneously expressed a 25-bp 2B-targeting and a 56-bp 3D-targeting shRNA. The 2B gene is involved in membrane rearrangements that are required for viral RNA replication and capsid assembly. The 3D gene encodes the RNA-dependent RNA polymerase, the fundamental protein that conducts viral genome replication. We did not employ a typical 19-bp shRNA because the 56- and 25-bp shRNA-corresponding sequences in different serotypes of FMDV were highly conserved, and these longer shRNAs had strong anti-FMDV effects[10, 12]. This phenomenon may be attributed to the potential diversity of the siRNA products made from long shRNAs by Dicer, which mimics the combination of multiple shRNAs.
The short half-life of siRNA/shRNA has always been a challenge for in vivo tests. In most reports, RNAi treatment might be effective only if the injection of siRNA/shRNA was performed within two days before the virus inoculation. In particular, the commonly used RNAi delivery system, recombinant adenovirus (rAd), has unavoidable shortcomings. The rAd-derived non-coding RNA VA1 can be expressed so strongly that it saturates the exportin-5 pathway, which is necessary for the transport of both foreign shRNA and cellular microRNA[33, 34]. The differential tissue distributions of rAd and FMDV are an additional complication. In this study, the MTCL were subjected to two rounds of monoclonal selection and were passaged at a 1:2 to 1:3 ratio 10 to 15 times before virus challenge, and F3 or F4 transgenic suckling mice underwent antiviral testing. Due to the genomic stability of our transgenic products, transgenic animals express natural resistance and do not require on-going precautionary inoculations.
The position effect is a major factor that determines transgene expression levels. Specifically, the expression of foreign genes is influenced by the chromosome structure surrounding the integration sites and cis-acting elements, such as enhancers and insulators. This effect makes the expression of transgenes unpredictable. Although we used polIII promoters (U6 and H1) instead of the polII promoter (for instance, CMV), which is usually used for foreign protein expression, a similar phenomenon was observed in our experiments. Assuming that the RNA expression level is positively related to the antiviral effect, the capacity of suppressing FMDV is the accumulation of all the integrating sites in the transgenic cell lines. As for the microinjection method in mouse experiments, however, foreign gene fragments tend to integrate into a few sites but with multiple copies. Once the fate of the entire transgene cluster is determined by its local position, the copy number and homozygous/hemizygous status do affect gene expression[37, 38]. In this study, we selected low-copy and hemizygous transgenic lines to avoid possible genetic side effects, such as chromosomal recombination and lethal homozygosity. This selection may partly explain the relatively limited antiviral capacities of the transgenic mouse lines. As primary cell selection and nuclear transfer is the principle technique of breeding large transgenic animals, locus control regions (LCR) or artificial chromosomes could be employed as position-independent delivery methods to elicit more efficient RNAi expression and to reduce the cost of selecting effective offspring.
In conclusion, we show that heritable FMDV resistance can be conferred by two endogenous shRNAs in susceptible cells and animals. To further improve this strategy, we are currently developing a multiple conserved region-targeting shRNA gene to confer strong, broad-spectrum resistance to FMDV infections of different serotypes. Additionally, novel transgenic methods in combination with conditional RNAi induction are expected to prevent side effects in livestock.
This work was supported by grants from the Chinese National Major Project of Breeding New Transgenic Species (2011ZX08006-001 and 2011ZX08007-004) to Mingqiu Liu and Zhaoxin Zheng, and a NSFC grant (31072112) to Mingqiu Liu.
We thank Professor Xiaohui Wu for kindly providing the piggyBac transposon-related plasmids and technical assistance. We also thank American Journal Experts for critically reading the manuscript.
- Pereira HG: Foot-and-mouth disease. Virus Diseases of Food Animals. Edited by: Gibbs EPJ. 1981, London: Academic Press Inc, 333-363.Google Scholar
- Goodwin EC, Rottman FM: The 3'-flanking sequence of the bovine growth-hormone gene contains novel elements required for efficient and accurate polyadenylation. J Biol Chem. 1992, 267: 16330-16334.PubMedGoogle Scholar
- King AMQ, Underwood BO, McCahon D, Newman JWI, Brown F: Biological identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature. 1981, 293: 479-480. 10.1038/293479a0.View ArticlePubMedGoogle Scholar
- Barteling SJ, Vreeswijk J: Developments in foot-and-mouth-disease vaccines. Vaccine. 1991, 9: 75-88. 10.1016/0264-410X(91)90261-4.View ArticlePubMedGoogle Scholar
- Fire A: RNA-triggered gene silencing. Trends Genet. 1999, 15: 358-363. 10.1016/S0168-9525(99)01818-1.View ArticlePubMedGoogle Scholar
- Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001, 98: 9742-9747. 10.1073/pnas.171251798.PubMed CentralView ArticlePubMedGoogle Scholar
- Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K: Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. 2003, 543: 51-54. 10.1016/S0014-5793(03)00400-9.View ArticlePubMedGoogle Scholar
- Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006, 439: 89-94. 10.1038/nature04263.View ArticlePubMedGoogle Scholar
- Jacque JM, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature. 2002, 418: 435-438. 10.1038/nature00896.View ArticlePubMedGoogle Scholar
- Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, Lu Y, Zheng Z: Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J Virol. 2006, 80: 3559-3566. 10.1128/JVI.80.7.3559-3566.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim SM, Lee KN, Park JY, Ko YJ, Joo YS, Kim HS, Park JH: Therapeutic application of RNA interference against foot-and-mouth disease virus in vitro and in vivo. Antiviral Res. 2008, 80: 178-184. 10.1016/j.antiviral.2008.06.001.View ArticlePubMedGoogle Scholar
- Cong W, Jin H, Jiang C, Yan W, Liu M, Chen J, Zuo X, Zheng Z: Attenuated salmonella choleraesuis-mediated RNAi targeted to conserved regions against foot-and-mouth disease virus in guinea pigs and swine. Vet Res. 2010, 41: 30-10.1051/vetres/2010002.PubMed CentralView ArticlePubMedGoogle Scholar
- Beck E, Strohmaier K: Subtyping of European foot-and-mouth-disease virus strains by nucleotide sequence determination. J Virol. 1987, 61: 1621-1629.PubMed CentralPubMedGoogle Scholar
- Gitlin L, Andino R: Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol. 2003, 77: 7159-7165. 10.1128/JVI.77.13.7159-7165.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Song EW, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K, Cerny J, Sharp PA, Lieberman J, Manjunath N, Shankar P: Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003, 77: 7174-7181. 10.1128/JVI.77.13.7174-7181.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Kahana R, Kuznetzova L, Rogel A, Shemesh M, Hai D, Yadin H, Stram Y: Inhibition of foot-and-mouth disease virus replication by small interfering RNA. J Gen Virol. 2004, 85: 3213-3217. 10.1099/vir.0.80133-0.View ArticlePubMedGoogle Scholar
- Kim SM, Lee KN, Lee SJ, Ko YJ, Lee HS, Kweon CH, Kim HS, Park JH: Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus. Antiviral Res. 2010, 87: 307-317. 10.1016/j.antiviral.2010.06.004.View ArticlePubMedGoogle Scholar
- Liu M, Chen W, Ni Z, Yan W, Fei L, Jiao Y, Zhang J, Du Q, Wei X, Chen J, Liu Y, Zheng Z: Cross-inhibition to heterologous foot-and-mouth disease virus infection induced by RNA interference targeting the conserved regions of viral genome. Virology. 2005, 336: 51-59. 10.1016/j.virol.2005.01.051.View ArticlePubMedGoogle Scholar
- Fahim M, Ayala-Navarrete L, Millar AA, Larkin PJ: Hairpin RNA derived from viral NIa gene confers immunity to wheat streak mosaic virus infection in transgenic wheat plants. Plant Biotechnol J. 2010, 8: 821-834. 10.1111/j.1467-7652.2010.00513.x.View ArticlePubMedGoogle Scholar
- Kanginakudru S, Royer C, Edupalli SV, Jalabert A, Mauchamp B, Chandrashekaraiah , Prasad SV, Chavancy G, Couble P, Nagaraju J: Targeting ie-1 gene by RNAi induces baculoviral resistance in lepidopteran cell lines and in transgenic silkworms. Insect Mol Biol. 2007, 16: 635-644. 10.1111/j.1365-2583.2007.00753.x.View ArticlePubMedGoogle Scholar
- Golding MC, Long CR, Carmell MA, Hannon GJ, Westhusin ME: Suppression of prion protein in livestock by RNA interference. Proc Natl Acad Sci USA. 2006, 103: 5285-5290. 10.1073/pnas.0600813103.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang PY, Jiang JJ, Li N, Sheng JL, Ren Y, Chen CF, Guo ZR: Transgenic mouse model integrating siRNA targeting the foot and mouth disease virus. Antiviral Res. 2010, 87: 265-268. 10.1016/j.antiviral.2010.02.319.View ArticleGoogle Scholar
- Ding S, Wu XH, Li G, Han M, Zhuang Y, Xu T: Efficient transposition of the piggyBac resource (PB) transposon in mammalian cells and mice. Cell. 2005, 122: 473-483. 10.1016/j.cell.2005.07.013.View ArticlePubMedGoogle Scholar
- Chen WZ, Yan WY, Du QY, Fei LA, Liu MQ, Ni Z, Sheng ZT, Zheng ZX: RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. J Virol. 2004, 78: 6900-6907. 10.1128/JVI.78.13.6900-6907.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Reed LJ, Muench HA: A simple method of estimating fifty percent end points. Am J Hyg. 1938, 27: 493-497.Google Scholar
- Hasuwa H, Kaseda K, Einarsdottir T, Okabe M: Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett. 2002, 532: 227-230. 10.1016/S0014-5793(02)03680-3.View ArticlePubMedGoogle Scholar
- Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Zhang M, McManus MT, Gertler FB, Scott ML, Van Parijs L: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003, 33: 401-406. 10.1038/ng1117.View ArticlePubMedGoogle Scholar
- Tiscornia G, Singer O, Ikawa M, Verma IM: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci US. 2003, 100: 1844-1848. 10.1073/pnas.0437912100.View ArticleGoogle Scholar
- Wang H, Wu J, Liu X, He H, Ding F, Yang H, Cheng L, Liu W, Zhong J, Dai Y, Li G, He C, Yu L, Li J: Identification of short hairpin RNA targeting foot-and-mouth disease virus with transgenic bovine fetal epithelium cells. PLoS One. 2012, 7: e42356-10.1371/journal.pone.0042356.PubMed CentralView ArticlePubMedGoogle Scholar
- Ter Brake O, Konstantinova P, Ceylan M, Berkhout B: Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006, 14: 883-892. 10.1016/j.ymthe.2006.07.007.View ArticlePubMedGoogle Scholar
- Grubman MJ, Baxt B: Foot-and-mouth disease. Clinl Microbiol Rev. 2004, 17: 465-493. 10.1128/CMR.17.2.465-493.2004.View ArticleGoogle Scholar
- O‘Reilly EK, Kao CC: Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology. 1998, 252: 287-303. 10.1006/viro.1998.9463.View ArticlePubMedGoogle Scholar
- Lu SH, Cullen BR: Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and microRNA biogenesis. J Virol. 2004, 78: 12868-12876. 10.1128/JVI.78.23.12868-12876.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Andersson MG, Haasnoot PCJ, Xu N, Berenjian S, Berkhout B, Akusjarvi G: Suppression of RNA interference by adenovirus virus-associated RNA. J Virol. 2005, 79: 9556-9565. 10.1128/JVI.79.15.9556-9565.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Cheng G, Chen W, Li Z, Yan W, Zhao X, Xie J, Liu M, Zhang H, Zhong Y, Zheng Z: Characterization of the porcine alpha interferon multigene family. Gene. 2006, 382: 28-38.View ArticlePubMedGoogle Scholar
- Karpen GH: Position-effect variegation and the new biology of heterochromatin. Curr Opin Genet Dev. 1994, 4: 281-291. 10.1016/S0959-437X(05)80055-3.View ArticlePubMedGoogle Scholar
- Kong Q, Wu M, Huan Y, Zhang L, Liu HY, Bou G, Luo Y, Mu Y, Liu Z: Transgene expression is associated with copy number and cytomegalovirus promoter methylation in transgenic pigs. PLoS One. 2009, 4: e6679-10.1371/journal.pone.0006679.PubMed CentralView ArticlePubMedGoogle Scholar
- Bueler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann C: High prion and PrPSc levels but delayed-onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med. 1994, 1: 19-30.PubMedGoogle Scholar
- Grosveld F, Vanassendelft GB, Greaves DR, Kollias G: Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell. 1987, 51: 975-985. 10.1016/0092-8674(87)90584-8.View ArticlePubMedGoogle Scholar
- Bian Q, Belmont AS: BAC TG-EMBED: one-step method for high-level, copy-number-dependent, position-independent transgene expression. Nucleic Acids Res. 2010, 38: e127-10.1093/nar/gkq178.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.